First Wave BioPharma Provides Update on IND Filing For Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency
January 13, 2023 16:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Results of Special Meeting of Stockholders
January 13, 2023 10:20 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 13, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Announces Adjournment of Special Meeting
January 09, 2023 09:10 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 09, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2023”
December 12, 2022 07:30 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase
December 05, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase
November 30, 2022 07:00 ET
|
First Wave BioPharma, Inc.
Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to...
First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock
November 25, 2022 17:45 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Closing of Private Placement
November 22, 2022 16:15 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Private Placement
November 21, 2022 08:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
November 16, 2022 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...